ImmuCell (ICCC) Earns Daily News Sentiment Rating of -0.08

ImmuCell (ICCC) Earns Daily News Sentiment Rating of -0.08

Media coverage about ImmuCell (NASDAQ:ICCC) has been trending somewhat negative recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ImmuCell earned a media sentiment score of -0.08 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.5327986477199 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Separately, ValuEngine upgraded ImmuCell from a “sell” rating to a “hold” rating in a report on Wednesday, October 18th.

ImmuCell (NASDAQ ICCC) traded up $0.44 during trading hours on Monday, hitting $7.49. The stock had a trading volume of 32,500 shares, compared to its average volume of 8,697. ImmuCell has a 52 week low of $5.00 and a 52 week high of $9.25. The company has a market capitalization of $37.83, a PE ratio of 749.00 and a beta of 1.18. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.99 and a current ratio of 1.75.

ImmuCell (NASDAQ:ICCC) last announced its earnings results on Monday, November 13th. The biotechnology company reported ($0.07) EPS for the quarter. ImmuCell had a net margin of 0.60% and a return on equity of 0.28%. The company had revenue of $2.01 million during the quarter.

COPYRIGHT VIOLATION WARNING: “ImmuCell (ICCC) Earns Daily News Sentiment Rating of -0.08” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/25/immucell-iccc-earns-daily-news-sentiment-rating-of-0-08.html.

ImmuCell Company Profile

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Insider Buying and Selling by Quarter for ImmuCell (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.

Media coverage about ImmuCell (NASDAQ:ICCC) has been trending somewhat negative recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ImmuCell earned a media sentiment score of -0.08 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.5327986477199 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Separately, ValuEngine upgraded ImmuCell from a “sell” rating to a “hold” rating in a report on Wednesday, October 18th.

ImmuCell (NASDAQ ICCC) traded up $0.44 during trading hours on Monday, hitting $7.49. The stock had a trading volume of 32,500 shares, compared to its average volume of 8,697. ImmuCell has a 52 week low of $5.00 and a 52 week high of $9.25. The company has a market capitalization of $37.83, a PE ratio of 749.00 and a beta of 1.18. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.99 and a current ratio of 1.75.

ImmuCell (NASDAQ:ICCC) last announced its earnings results on Monday, November 13th. The biotechnology company reported ($0.07) EPS for the quarter. ImmuCell had a net margin of 0.60% and a return on equity of 0.28%. The company had revenue of $2.01 million during the quarter.

COPYRIGHT VIOLATION WARNING: “ImmuCell (ICCC) Earns Daily News Sentiment Rating of -0.08” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/25/immucell-iccc-earns-daily-news-sentiment-rating-of-0-08.html.

ImmuCell Company Profile

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Insider Buying and Selling by Quarter for ImmuCell (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply